Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.Ask about treatment

Duchenne muscular dystrophy (DMD): US-approved treatments and how families in the Gulf can access them

Name: Duchenne muscular dystrophy: treatments and Gulf access | Reserve Meds
Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Duchenne muscular dystrophy: the short answer

The US FDA has approved seven medicines covered on this page for Duchenne muscular dystrophy, each for a specific group of patients: Elevidys, Duvyzat, Agamree, Exondys 51, Vyondys 53, Viltepso and Amondys 45. On 17 October 2026, six of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Elevidys, Duvyzat, Agamree, Exondys 51, Vyondys 53, Viltepso and Amondys 45.
Gulf registers (checked 17 October 2026): see each medicine below.
Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital; cell and gene therapies at a qualified center.
Price: Quote on request.

What is Duchenne muscular dystrophy?

Muscular dystrophies are genetic conditions that cause progressive muscle weakness and wasting. Duchenne muscular dystrophy (DMD) affects the muscles used for movement and the heart muscle, and it occurs almost exclusively in males.^[1]

In boys with DMD, muscle weakness appears in early childhood and worsens quickly. They may be late to sit, stand and walk, and are usually wheelchair-dependent by adolescence. Becker muscular dystrophy is a related, usually milder condition caused by changes in the same gene.^[1]

Duchenne and Becker muscular dystrophies together affect 1 in 3,500 to 5,000 newborn males worldwide. Some US-approved medicines work only for boys with specific changes in the DMD gene, so genetic testing is important.^{[1, 2]}

Duchenne muscular dystrophy in the Gulf

Duchenne muscular dystrophy in Saudi Arabia was reviewed in Frontiers in Neurology in 2024, and a 2022 paper discussed gene therapy opportunities for DMD in the Middle East.^{[3, 4]}

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 0 of 7 were listed in Saudi Arabia and 6 of 7 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.^{[5, 6]}

US FDA-approved medicines for Duchenne muscular dystrophy

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Elevidys (delandistrogene moxeparvovec-rokl)
US FDA-approved for patients 4 years and older with DMD who can walk and have a confirmed mutation in the DMD gene. It is a one-time gene therapy given by infusion at a qualified center.^[7]
Current US label version: 12 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Duvyzat (givinostat)
US FDA-approved for DMD in patients 6 years and older. It is an oral suspension.^[8]
Current US label version: 21 November 2024. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Agamree (vamorolone)
US FDA-approved for DMD in patients 2 years and older. It is a corticosteroid oral suspension.^[9]
Current US label version: 22 January 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Egypt, Turkey, India, Pakistan
Exondys 51 (eteplirsen)
US FDA-approved for DMD in patients with a confirmed mutation amenable to exon 51 skipping. It is a weekly infusion.^[2]
Current US label version: 13 August 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Vyondys 53 (golodirsen)
US FDA-approved for DMD in patients with a confirmed mutation amenable to exon 53 skipping. It is a weekly infusion.^[10]
Current US label version: 13 March 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Viltepso (viltolarsen)
US FDA-approved for DMD in patients with a confirmed mutation amenable to exon 53 skipping. It is a weekly infusion.^[11]
Current US label version: 16 July 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
Amondys 45 (casimersen)
US FDA-approved for DMD in patients with a confirmed mutation amenable to exon 45 skipping. It is a weekly infusion.^[12]
Current US label version: 9 January 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.^{[5, 6]}
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.^{[13, 14]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

For Elevidys. These are made for one patient or given through a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center that can give the treatment, which may be abroad. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves. We cannot promise that a manufacturer will agree.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for Duchenne muscular dystrophy

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for Duchenne muscular dystrophy?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Elevidys, Duvyzat, Agamree, Exondys 51, Vyondys 53, Viltepso and Amondys 45. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Elevidys available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Elevidys?

It is given at a qualified center. Your specialist refers the patient, the center checks eligibility, and the family plans funding and travel. A local hospital can only give it if the manufacturer agrees to supply it and the regulator approves.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

What does exon skipping mean?

Exondys 51, Vyondys 53, Viltepso and Amondys 45 are approved only for boys whose DMD gene change is amenable to skipping a specific exon (51, 53 or 45). A genetic report shows whether this applies.

Sources for the condition-specific answers: ^{[2, 10, 11, 12]}

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.